Yao-long CHEN, Jian-jian WANG, Si-yan ZHAN, Jian SUN, Ying-hui JIN, Hui LI, Hong-cai SHANG, Ke-hu YANG. How to Address Conflicts of Interest in Clinical Practice Guidelines[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 685-691. doi: 10.3969/j.issn.1674-9081.2019.06.023
Citation: Yao-long CHEN, Jian-jian WANG, Si-yan ZHAN, Jian SUN, Ying-hui JIN, Hui LI, Hong-cai SHANG, Ke-hu YANG. How to Address Conflicts of Interest in Clinical Practice Guidelines[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 685-691. doi: 10.3969/j.issn.1674-9081.2019.06.023

How to Address Conflicts of Interest in Clinical Practice Guidelines

doi: 10.3969/j.issn.1674-9081.2019.06.023
More Information
  • Corresponding author: CHEN Yao-long Tel: 86-931-8912639, E-mail:chenyaolong@vip.163.com
  • Received Date: 2019-10-31
  • Publish Date: 2019-11-30
  • Conflicts of interest can affect the credibility, independence, and quality of clinical practice guidelines. Guideline developers, users, and researchers are trying to manage and reduce conflicts of interest worldwide. In this article, we analyzed and compared the definition, classification, and management strategies of conflicts of interest of the key national and international guideline developers, and give recommendations on how to address conflicts of interest in clinical practice guidelines in China.
  • loading
  • [1] Institute of Medicine.Clinical practice guidelines we can trust[M].Washington (DC):National Academies Press, 2011.
    [2] Djulbegovic B, Guyatt GH.Progress in evidence-based medicine:a quarter century on[J].Lancet, 2017, 390:415-423. doi:  10.1016/S0140-6736(16)31592-6
    [3] 陈耀龙, 罗旭飞, 王吉耀, 等.如何区分临床实践指南与专家共识[J].协和医学杂志, 2019, 10:403-408. http://www.cnki.com.cn/Article/CJFDTotal-XHYX201904018.htm
    [4] 陈耀龙, 马艳芳, 周奇, 等.谁应该参与临床实践指南的制订?[J].协和医学杂志, 2019, 10:524-530. http://www.cnki.com.cn/Article/CJFDTotal-XHYX201905018.htm
    [5] Chen Y, Yang K, Norris SL.Managing conflicts of interest in practice guidelines panels[J].JAMA, 2017, 318:866-867.
    [6] Sox HC.Conflict of interest in practice guidelines panels[J].JAMA, 2017, 317:1739-1740. doi:  10.1001/jama.2017.2701
    [7] Schünemann HJ, Al-Ansary LA, Forland F, et al.Guidelines International Network:principles for disclosure of interests and management of conflicts in guidelines[J].Ann Intern Med, 2015, 163:548-553. doi:  10.7326/M14-1885
    [8] Norris SL, Holmer HK, Ogden LA, et al.Conflict of interest in clinical practice guideline development:a systematic review[J].PLoS One, 2011, 6:e25153. doi:  10.1371/journal.pone.0025153
    [9] Kanter GP, Loewenstein G.Evaluating open payments[J].JAMA, 2019.doi:10./001/jama.2019.8171.[Epub ahead of print].
    [10] Gao Y, Wang J, Luo X, et al.Quality appraisal of clinical practice guidelines for diabetes mellitus published in China between 2007 and 2017 using the AGREE Ⅱ instrument[J].BMJ Open, 2019, 9:e022392. doi:  10.1136/bmjopen-2018-022392
    [11] 陈耀龙, 周奇, 崔荣荣, 等.基于AGREEⅡ的中医药临床指南质量评价[J].中国循证医学杂志, 2016, 16:1331-1337. http://www.cnki.com.cn/Article/CJFDTotal-ZZXZ201611013.htm
    [12] 李楠, 姚亮, 吴琼芳, 等.2012-2013年中国大陆期刊发表临床实践指南质量评价[J].中国循证医学杂志, 2015, 15:259-263. http://www.cnki.com.cn/Article/CJFDTotal-ZZXZ201503003.htm
    [13] 韦当, 王小琴, 吴琼芳, 等.2011年中国临床实践指南质量评价[J].中国循证医学杂志, 2013, 13:760-763. http://www.cnki.com.cn/Article/CJFDTotal-ZZXZ201306028.htm
    [14] Hu J, Chen R, Wu S, et al.The quality of clinical practice guidelines in China:a systematic assessment[J].J Eval Clin Pract, 2013, 19:961-967.
    [15] Chen YL, Yao L, Xiao XJ, et al.Quality assessment of clinical guidelines in China:1993-2010[J].Chin Med J, 2012, 125:3660-3664. https://www.ncbi.nlm.nih.gov/pubmed/23075720
    [16] 柯立鑫, 王津京, 王浩, 等.2016年中国大陆期刊发表临床实践指南的报告质量评价[J].中国循证儿科杂志, 2018:194-199. http://www.cnki.com.cn/Article/CJFDTotal-XZEK201803009.htm
    [17] 令娟, 王明霞, 王琪, 等.2015年中国临床实践指南的报告质量分析[J].中国循证医学杂志, 2018, 18:721-728. http://www.cnki.com.cn/Article/CJFDTotal-ZZXZ201807014.htm
    [18] 陈耀龙, 商洪才, 杨克虎, 等.临床实践指南的国际经验和中国道路[J].协和医学杂志, 2019, 10:289-292. http://www.cnki.com.cn/Article/CJFDTotal-XHYX201903018.htm
    [19] World Health Organization.WHO handbook for guideline development.Second edition[M/OL].2014. http://apps.who.int/medicinedocs/en/m/abstract/Js22083en/.
    [20] Schüunemann HJ, Osborne M, Moss J, et al.An official American Thoracic Society Policy statement:managing conflict of interest in professional societies[J].Am J Respir Crit Care Med, 2009, 180:564-580. doi:  10.1164/rccm.200901-0126ST
    [21] Qaseem A, Wilt TJ, Clinical Guidelines Committee of the American College of Physicians.Disclosure of interests and management of conflicts of interest in clinical guidelines and guidance statements:methods from the Clinical Guidelines Committee of the American College of Physicians[J].Ann Intern Med, 2019, 171:354-361. doi:  10.7326/M18-3279
    [22] Guyatt G, Akl EA, Hirsh J, et al.The vexing problem of guidelines and conflict of interest:a potential solution[J].Ann Intern Med, 2010, 152:738-741. doi:  10.7326/0003-4819-152-11-201006010-00254
    [23] Akl EA, El-Hachem P, Abou-Haidar H, et al.Consider-ing intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline:a descriptive study[J].J Clin Epidemiol, 2014, 67:1222-1228. doi:  10.1016/j.jclinepi.2014.05.006
    [24] Akl EA, Karl R, Guyatt GH.Methodologists and context experts disagreed regarding managing conflicts of interest of clinical practice guidelines panels[J].J Clin Epidemiol, 2012, 65:734-739. doi:  10.1016/j.jclinepi.2011.12.013
    [25] 宋霄杨, 高玉婷, 周奇, 等.非经济利益冲突及其研究现状[J].中国循证医学杂志, 2017, 17:607-611. http://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201705018.htm
    [26] Bernard L, Marilyn JF.Conflict of Interest in Medical Research, Education, and Practice[M].Washington (DC):National Academies Press (US), 2009:190-210.
    [27] Norris SL, Burda BU, Holmer HK, et al.Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography[J].J Clin Epidemiol, 2012, 65:725-733. doi:  10.1016/j.jclinepi.2011.12.011
    [28] Sinclair D, Isba R, Kredo T, et al.World Health Organization guideline development:an evaluation[J].PLoS One, 2013, 8:e63715. doi:  10.1371/journal.pone.0063715
    [29] Niforatos JD, Pescatore RM.Financial relationships with industry among guideline authors for the management of acute ischemic stroke[J].Am J Emerg Med, 2019, 37:921-923. doi:  10.1016/j.ajem.2019.01.037
    [30] Saito H, Ozaki A, Sawano T, et al.Evaluation of pharmaceutical company payments and conflict of interest disclo-sures among oncology clinical practice guideline authors in Japan[J].JAMA Netw Open, 2019, 2:e192834. doi:  10.1001/jamanetworkopen.2019.2834
    [31] Hart KL, Perlis RH, Perlis CS.Conflict of interest and citation impact among dermatology guideline authors[J].J Am Acad Dermatol, 2019, 80:813-815. doi:  10.1016/j.jaad.2018.10.028
    [32] Irwig MS, Kyinn M, Shefa MC.Financial conflicts of interest among authors of Endocrine Society clinical practice guidelines[J].J Clin Endocrinol Metab, 2018, 103:4333-4338. doi:  10.1210/jc.2018-00526
    [33] Carlisle A, Bowers A, Wayant C, et al.Financial conf-licts of interest among authors of urology clinical practice guidelines[J].Eur Urol, 2018, 74:348-354. doi:  10.1016/j.eururo.2018.04.023
    [34] Horn J, Checketts JX, Jawhar O, et al.Evaluation of industry relationships among authors of otolaryngology clinical practice guidelines[J].JAMA Otolaryngol Head Neck Surg, 2018, 144:194-201. doi:  10.1001/jamaoto.2017.2741
    [35] Jefferson AA, Pearson SD.Conflict of interest in seminal hepatitis C virus and cholesterol management guidelines[J].JAMA Intern Med, 2017, 177:352-357. doi:  10.1001/jamainternmed.2016.8439
    [36] 王强, 黄超, 李俊, 等.2017年中国发布的临床实践指南中利益冲突与经济学证据的调查分析[J].中国循证医学杂志, 2018, 18:379-387. http://www.cnki.com.cn/Article/CJFDTotal-ZZXZ201804019.htm
    [37] Brouwers MC, Kho ME, Browman GP, et al.AGREE Ⅱ:advancing guideline development, reporting and evaluation in health care[J].CMAJ, 2010, 182:E839-842. doi:  10.1503/cmaj.090449
    [38] Chen Y, Yang K, Marušic A, et al.A reporting tool for practice guidelines in health Care:The RIGHT Statement[J].Ann Intern Med, 2017, 166:128-132. doi:  10.7326/M16-1565
    [39] 蒋朱明, 詹思延, 贾晓巍, 等.制订/修订《临床诊疗指南》的基本方法及程序[J].中华医学杂志, 2016, 96:250-253. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_zhyx201604007
    [40] Centers for Medicare & Medicaid Services.Open Payments[DB/OL]. https://www.cms.gov/openpayments/.
    [41] 肖淑君, 高玉婷, 王小琴, 等.患者指南及其制订方法介绍[J].药品评价, 2017, 14:44-48. http://www.cnki.com.cn/Article/CJFDTotal-YPPJ201706007.htm
    [42] 王小琴, 童雅婧, 何江华, 等.患者指南制订的基本原则和方法(一)[J].中国循证儿科杂志, 2017, 12:476-478. http://www.cnki.com.cn/Article/CJFDTotal-XZEK201706020.htm
    [43] 詹思延, 尹道馨, 唐金陵.中国临床指南:解决利益冲突和吸纳患者参与[J].英国医学杂志(中文版), 2019, 22:33-34.
    [44] Zhan SY, Yin DX, Tang JL.Clinical guidelines in China: tackling conflict of interests and engaging patients[EB/OL].https://blogs.bmj.com/bmj/2018/11/06/clinical-guidelines-in-china-tackling-conflict-of-interests-and-engaging-patients/.
    [45] 王洋洋, 陈耀龙, 王小琴, 等.中医(中西医结合)临床实践指南制修订方法——利益冲突声明与管理[J].中华中医药杂志, 2016, 31:3613-3616. http://www.cnki.com.cn/Article/CJFDTotal-BXYY201609061.htm
    [46] 赵明娟, 靳英辉, 张菁, 等.临床实践指南制定方法——利益冲突的声明和管理[J].中国循证心血管医学杂志, 2018, 10:513-517.
    [47] 刘峘, 谢雁鸣, 王永炎.中医药临床实践指南制订过程中的利益冲突与声明[J].中医杂志, 2017, 58:2001-2003. http://www.cnki.com.cn/Article/CJFDTotal-ZZYZ201723006.htm
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Article Metrics

    Article views (609) PDF downloads(205) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return